Erythropoietin in Tumor Immunity: Mechanistic Evidence, Clinical Cautions, and Translational Opportunities

Tongsheng Yang, Linxing Zheng, Tian Lan

Open source

DOI
10.3390/cancers18183011
Published
2026-09-17
Container
Cancers
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/cancers18183011,
  title = {Erythropoietin in Tumor Immunity: Mechanistic Evidence, Clinical Cautions, and Translational Opportunities},
  author = {Tongsheng Yang and Linxing Zheng and Tian Lan},
  year = {2026},
  journal = {Cancers},
  doi = {10.3390/cancers18183011},
  url = {https://doi.org/10.3390/cancers18183011}
}

RIS

TY  - JOUR
TI  - Erythropoietin in Tumor Immunity: Mechanistic Evidence, Clinical Cautions, and Translational Opportunities
AU  - Tongsheng Yang
AU  - Linxing Zheng
AU  - Tian Lan
PY  - 2026
JO  - Cancers
DO  - 10.3390/cancers18183011
UR  - https://doi.org/10.3390/cancers18183011
ER  - 

APA

Yang, T., Zheng, L., & Lan, T. (2026). Erythropoietin in Tumor Immunity: Mechanistic Evidence, Clinical Cautions, and Translational Opportunities. Cancers. https://doi.org/10.3390/cancers18183011

Source records